H.C. Wainwright keeps USD 20.00 target for Enanta Pharmaceuticals stock

Published on 10/17/2026 at 21:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Earnings are due November 16, 2026. Enanta Pharmaceuticals stock costs USD 11.10 on October 16, 2026, down 3.23 percent versus Nasdaq close.

Analyst view and reporting date

On September 23, 2026, H.C. Wainwright reiterated a USD 20.00 target for Enanta Pharmaceuticals.
The next earnings date is November 16, 2026.
Enanta Pharmaceuticals stock cost USD 11.10 at Nasdaq on October 16, 2026 at 4:00 p.m. EDT, down 3.23 percent versus the prior Nasdaq close.
Market capitalization stood at USD 323.3 million on October 16, 2026, with a price-to-earnings ratio of -4.61.

ENTA, US29251M1062, Illustration mit AI erstellt.

H.C. Wainwright reiterated a Buy rating and a USD 20.00 target for Enanta Pharmaceuticals in a report dated September 23, 2026, according to MarketBeat. The target is 80.18 percent above the Nasdaq price of USD 11.10. On Nasdaq, the stock last traded at USD 11.10 on October 16, 2026 at 4:00 p.m. EDT, down 3.23 percent versus the prior Nasdaq close.

Earnings date is November 16

TradingView lists November 16, 2026 as Enanta Pharmaceuticals' next earnings date. The appointment gives investors a defined point for testing the company's cash position, research spending and revenue outlook.

Range runs from USD 10.20

The October 16 Nasdaq range was USD 10.94 to USD 11.41, while volume reached 184,694 shares against an average of 231,476. The session price stood 35.28 percent below the 52-week high of USD 17.15 and 8.82 percent above the 52-week low of USD 10.20. The current level therefore sits materially closer to the yearly floor than to the yearly ceiling.

Valuation and company scale

Enanta Pharmaceuticals had a market capitalization of USD 323.3 million and a negative price-to-earnings ratio of -4.61 on October 16, 2026. The Massachusetts biotechnology company develops small-molecule treatments for viral and immunological diseases, including respiratory syncytial virus programs, according to its investor-relations page.

Comparison with peers

Enanta Pharmaceuticals (Nasdaq, USD): minus 3.23 percent, P/E -4.61, market capitalization USD 323.3 million
Vir Biotechnology (Nasdaq, USD): minus 4.87 percent, P/E -5.35, market capitalization USD 1.7 billion
Madrigal Pharmaceuticals (Nasdaq, USD): minus 2.19 percent, P/E -34.89, market capitalization USD 10.4 billion

The next Nasdaq session

The analyst target and the November reporting date frame the next valuation discussion, while the price remains below its yearly high. Enanta's latest fiscal third-quarter revenue was USD 14.36 million for the period ended June 30, 2026, and its net loss was USD 19.50 million, according to the standardized quarterly figures. The revenue figure was below the USD 16.76 million consensus estimate reported by MarketBeat.

The last Nasdaq price was USD 11.10 on October 16, 2026 at 4:00 p.m. EDT, down 3.23 percent versus the prior Nasdaq close.